Evidence map›Paper›PMID 25493436›Full record

Observational studyPloS one2014

Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study.

Michael Lever, Peter M George, Sandy Slow, David Bellamy, Joanna M Young, Markus Ho, Christopher J McEntyre, Jane L Elmslie, Wendy Atkinson, Sarah L Molyneux and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 11 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 11 syntheses or guidelines pooled it, 223 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Michael LeverClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand; Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
Peter M GeorgeClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand; Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
Sandy SlowClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand; Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
David BellamyClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Joanna M YoungThe Christchurch Heart Institute, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Markus HoClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Christopher J McEntyreClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Jane L ElmslieClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Wendy AtkinsonClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Sarah L MolyneuxClinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand.
Richard W TroughtonThe Christchurch Heart Institute, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Christopher M FramptonThe Christchurch Heart Institute, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
A Mark RichardsThe Christchurch Heart Institute, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Stephen T ChambersDepartment of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
Canterbury Health Laboratories · NZUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBetaine is a major osmolyte, also important in methyl group metabolism. Concentrations of betaine, its metabolite dimethylglycine and analog trimethylamine-N-oxide (TMAO) in blood are cardiovascular risk markers. Diabetes disturbs betaine: does diabetes alter associations between betaine-related measures and cardiovascular risk?

methodsPlasma samples were collected from 475 subjects four months after discharge following an acute coronary admission. Death (n = 81), secondary acute MI (n = 87), admission for heart failure (n = 85), unstable angina (n = 72) and all cardiovascular events (n = 283) were recorded (median follow-up: 1804 days).

resultsHigh and low metabolite concentrations were defined as top or bottom quintile of the total cohort. In subjects with diabetes (n = 79), high plasma betaine was associated with increased frequencies of events; significantly for heart failure, hazard ratio 3.1 (1.2-8.2) and all cardiovascular events, HR 2.8 (1.4-5.5). In subjects without diabetes (n = 396), low plasma betaine was associated with events; significantly for secondary myocardial infarction, HR 2.1 (1.2-3.6), unstable angina, HR 2.3 (1.3-4.0), and all cardiovascular events, HR 1.4 (1.0-1.9). In diabetes, high TMAO was a marker of all outcomes, HR 2.7 (1.1-7.1) for death, 4.0 (1.6-9.8) for myocardial infarction, 4.6 (2.0-10.7) for heart failure, 9.1 (2.8-29.7) for unstable angina and 2.0 (1.1-3.6) for all cardiovascular events. In subjects without diabetes TMAO was only significant for death, HR 2.7 (1.6-4.8) and heart failure, HR 1.9 (1.1-3.4). Adding the estimated glomerular filtration rate to Cox regression models tended to increase the apparent risks associated with low betaine.

conclusionsElevated plasma betaine concentration is a marker of cardiovascular risk in diabetes; conversely low plasma betaine concentrations indicate increased risk in the absence of diabetes. We speculate that the difference reflects control of osmolyte retention in tissues. Elevated plasma TMAO is a strong risk marker in diabetes.

Indexed as

Acute Coronary SyndromeAgedAged, 80 and overBetaineBiomarkersCardiovascular DiseasesCase-Control StudiesDiabetes Mellitus, Type 2FemaleHumansKaplan-Meier EstimateMaleMethylaminesMiddle AgedProportional Hazards ModelsRisk FactorsBetaineBiomarkersMethylaminestrimethyloxamine

Identifiers

PMID25493436
PMCPMC4262445
OpenAlexW2045387428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.